Expression of CCL5 can also be epigenetically regulated as shown by the study in non-small cell lung cancer showing that a combination of DNA-demethylating agents with histone deacetylase inhibitors reversed tumor immune evasion and modulated the T cell phenotype away from a T cell exhaustion state toward memory and effector T cell phenotypes (162). The gene discussed is CCL5; the disease is neoplasm.